> Hansanant, N., Cao, K., Tenorio, A., Joseph, T., Ju, M., McNally, N., Kummari, E., Williams, M., Cothrell, A., Buhrow, A.R., Shin, R., Orugunty, R., & Smith, L. (2024). Previously uncharacterized variants, OCF-E—J, of the antifungal occidiofungin produced by Burkholderia contaminans MS14. *Journal of Natural Products, 87*(2), 186-194. https://doi.org/10.1021/acs.jnatprod.3c00777 This article describes the discovery and characterization of a wide array of novel variants of occidiofungin. I began contributed to the investigation of these variants, with a focus on OCF-J, during my time at Sano Chemicals from 2018 to 2021 isolating and purifying occidiofungin and concerning myself with the ratios of these compounds in different modes of production. Nopakorn Hansanant, the primary author, and I were then fellow graduate students from 2021 through 2024 as he continued his work characterizing the structures of these compounds and their potency *in vitro*. I continue to investigate the origin of variability in the structure of the occidiofungin at amino acid position 7 today as one of the major parts of my Ph.D. studies. --- > Jonika, M.M., Alfieri, J.M., Sylvester, T., Buhrow, A.R. & Blackmon, H. (2022). Why not Y naught. *Heredity, 129*(2), 75-78. https://doi.org/10.1038/s41437-022-00543-z This short perspective article discusses current evidence for the absence of YO and WO sex determination systems across the tree of life and some lines of thinking surrounding that absence. I had the opportunity to contribute to this article while rotating as a graduate student with Dr. Heath Blackmon in late 2021. --- > Ju, M., Joseph, T., Hansanant, N., Geng, M., Williams, M., Cothrell, A., Buhrow, A.R., Austin, F., & Smith, L. (2022). Evaluation of analogs of mutacin 1140 in systemic and cutaneous methicillin-resistant Staphylococcus aureus infection models in mice. *Frontiers in Microbiology, 13*, 1067410. https://doi.org/10.3389/fmicb.2022.1067410 In this paper we investigated the efficacy of mutacin 1140 and its analogs K2A and R13A in mice. I worked with several authors that were in the lab at the time on the murine efficacy work for those analogs. --- > Foxfire, A., Buhrow, A.R., Orugunty, R.S., & Smith, L. (2021). Drug discovery through the isolation of natural products from Burkholderia. *Expert opinion on drug discovery, 16*(7), 807-822. https://doi.org/10.1080/17460441.2021.1877655 This review article discusses the wide array of antimicrobial compounds produced by *Burkholderia* species, including siderophores, burkholdines, occidiofungin, and other such compounds. I worked on it as a shared first author near the end of my Bachelor's degree at Texas A&M while employed at Sano Chemicals, as a research scientist manufacturing and studying occidiofungin.